Karyopharm
Newton, US · 3 known investors
Karyopharm Therapeutics is a commercial-stage pharmaceutical company that discovers and develops oral cancer therapies for disease areas with high unmet need. It is a leader in Selective Inhibitor of Nuclear Export (SINE) technology and XPO1 inhibition, with programs in indications such as myelofibrosis and endometrial cancer.
Founders & leadership
PH
Peter HonigDirector
BE
Barry E. GreeneDirector
SP
Stuart PoultonExecutive Officer
MM
Michael ManoExecutive Officer
RR
Reshma RangwalaExecutive Officer
RP
Richard PaulsonExecutive Officer, Director
DR
Deepika R. PakianathanDirector
CS
Chen SchorDirector
SM
Stephen MitchenerExecutive Officer
MM
Michael MasonExecutive Officer
MR
Mansoor Raza MirzaDirector
GG
Garen G. BohlinDirector
Investors · 3
Reported raises · per SEC filings
Form D private placements▶$165MraisedDec 2022 · 33 investors · PharmaceuticalsRule 506(b)
▶$165MraisedDec 2022 · 33 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter HonigDirector
- Barry E. GreeneDirector
- Stuart PoultonExecutive Officer
- Michael ManoExecutive Officer
- Reshma RangwalaExecutive Officer
- Richard PaulsonExecutive Officer, Director
- Deepika R. PakianathanDirector
- Chen SchorDirector
- Stephen MitchenerExecutive Officer
- Michael MasonExecutive Officer
- Mansoor Raza MirzaDirector
- Garen G. BohlinDirector
- Christy J. OligerDirector
- Sohanya ChengExecutive Officer
- Offering amount
- $165M
- Amount sold
- $165M
- Sales commissions
- $9.9M
- Placement agents
- Robert W. Baird & Co. Incorporated, Piper Sandler & Co., Jefferies LLC, Barclays Capital, Inc., H.C. Wainwright & Co. LLC
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.